MDL Won't Stop PTAB From Reviewing Merck Diabetes Patent
The Patent Trial and Appeal Board will review whether claims of a Merck patent covering the blockbuster diabetes drugs Januvia and Janumet are invalid, shooting down a variety of arguments from...To view the full article, register now.
Already a subscriber? Click here to view full article